Unknown

Dataset Information

0

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.


ABSTRACT: Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with refractory/recurrent disease. We generated five lentiviral vectors encoding CD20, which may serve as a target for CAR T cell depletion, and 2nd or 3rd generation CD123-CARs since the benefit of two costimulatory domains is model dependent. Four CARs were based on the CD123-specific single-chain variable fragment (scFv) 26292 (292) and one CAR on the CD123-specific scFv 26716 (716), respectively. We designed CARs with different hinge/transmembrane (H/TM) domains and costimulatory domains, in combination with the zeta (z) signaling domain: 292.CD8aH/TM.41BBz (8.41BBz), 292.CD8aH/TM.CD28z (8.28z), 716.CD8aH/TM.CD28z (716.8.28z), 292.CD28H/TM. CD28z (28.28z), and 292.CD28H/TM.CD28.41BBz (28.28.41BBz). Transduction efficiency, expansion, phenotype, and target cell recognition of the generated CD123-CAR T cells did not significantly differ. CAR constructs were eliminated for the following reasons: (1) 8.41BBz CARs induced significant baseline signaling, (2) 716.8.28z CAR T cells had decreased anti-AML activity, and (3) CD28.41BBz CAR T cells had no improved effector function in comparison to CD28z CAR T cells. We selected the 28.28z CAR since CAR expression on the cell surface of transduced T cells was higher in comparison to 8.28z CARs. The clinical study (NCT04318678) evaluating 28.28z CAR T cells is now open for patient accrual.

SUBMITTER: Riberdy JM 

PROVIDER: S-EPMC7393323 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.

Riberdy Janice M JM   Zhou Sheng S   Zheng Fei F   Kim Young-In YI   Moore Jennifer J   Vaidya Abishek A   Throm Robert E RE   Sykes April A   Sahr Natasha N   Bonifant Challice L CL   Ryu Byoung B   Gottschalk Stephen S   Velasquez Mireya Paulina MP  

Molecular therapy. Methods & clinical development 20200630


Chimeric antigen receptor (CAR) T cells targeting CD123, an acute myeloid leukemia (AML) antigen, hold the promise of improving outcomes for patients with refractory/recurrent disease. We generated five lentiviral vectors encoding CD20, which may serve as a target for CAR T cell depletion, and 2<sup>nd</sup> or 3<sup>rd</sup> generation CD123-CARs since the benefit of two costimulatory domains is model dependent. Four CARs were based on the CD123-specific single-chain variable fragment (scFv) 26  ...[more]

Similar Datasets

| S-EPMC6511336 | biostudies-literature
| S-EPMC7461863 | biostudies-literature
| S-EPMC5669573 | biostudies-literature
| S-EPMC5363190 | biostudies-literature
| S-EPMC3585808 | biostudies-literature
| S-EPMC5542631 | biostudies-literature
| S-EPMC8310147 | biostudies-literature
| S-EPMC3814731 | biostudies-literature
| S-EPMC6612629 | biostudies-literature
| S-EPMC4624420 | biostudies-literature